News from Cancer Discovery

• Exact Sciences Buys Genomic Health for $2.8 Billion
  Combined entity may expand range of diagnostic tests beyond Cologuard, Oncotype DX.
• Neoadjuvant Pembrolizumab Takes on TNBC
  Preliminary results suggest that the PD-1 inhibitor plus chemo elicits a higher pCR rate than chemo alone.
• RNA Technologies Expand Tool Kit for Cancer Immunotherapy
  Novel platform for making vaccines and immunomodulatory factors shows promise in early-stage testing.